GlassScriptPhysician profile
Ashlee L Capponi
NPI 1205373560
$3,897.00
in general payments reported to CMS, 2019-2025
21 companies · $1,885 in 2025
The $1,885 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $53.69 · 2023: $312 · 2024: $1,647 · 2025: $1,885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,758 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,758.32 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $831.10 | 2022-2025 | |
| Pfizer INC. | $475.53 | 2024-2025 | |
| Janssen Biotech, INC. | $423.74 | 2024-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $309.28 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $289.10 | 2024-2025 | Entyvio, Eohilia |
| Phathom Pharmaceuticals, INC. | $221.63 | 2024 | Voquezna |
| Aimmune Therapeutics, INC. | $202.40 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $192.05 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $158.46 | 2023-2025 | |
| Lilly USA, LLC | $118.11 | 2024-2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.91 | 2024-2025 | Trulance, Xifaxan |
| Intercept Pharmaceuticals, INC. | $88.21 | 2024-2025 | |
| Ironwood Pharmaceuticals, INC | $81.72 | 2024 | |
| Celgene Corporation | $76.91 | 2023-2024 | Zeposia |
| Braintree Laboratories, INC. | $71.69 | 2023 | Suflave, Sutab |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $71.55 | 2025 | Dupixent |
| Novo Nordisk INC | $53.45 | 2025 | Wegovy |
| Amgen INC. | $37.04 | 2025 | Uplizna |
| Ipsen Biopharmaceuticals, INC | $29.84 | 2025 | Iqirvo |
| Boston Scientific Corporation | $28.49 | 2025 | Wavewriter Alpha Prime 16 |
| Mirum Pharmaceuticals, INC. | $24.79 | 2024 | Livmarli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashlee Capponi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.